Drugs@FDA document

DOXIL (LIPOSOMAL) Letter · NDA 050718 SUPPL-60

Drugs@FDA document · BAXTER HLTHCARE CORP · May 9, 2022

Key facts

Drug name DOXIL (LIPOSOMAL)
Document type Letter
Application NDA050718
Submission SUPPL-60
Company BAXTER HLTHCARE CORP
Document date May 9, 2022
FDA document accessdata.fda.gov

At a glance

  • Labeling-Container/Carton Labels, Labeling-Package Insert Document categories
  • 10–99 Documents for this application
  • None USP chapters cited in this application's documents

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About Drugs@FDA documents

Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.

Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date:

Browse all Drugs@FDA documents